Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI)

Carlo Di Mario; Leonardo Bolognese; Luc Maillard; Dariusz Dudek; Giampaolo Gambarati; Antonio Manari; Vincenzo Guiducci; Giampiero Patrizi; Luigi Cesare Rusconi; Giancarlo Piovaccari; Agnes Ricard Hibon; Vanessa Belpomme; Ciro Indolfi; Zoran Olivari; Giuseppe Steffenino; Krzysztof Zmudka; Flavio Airoldi; Rita Panzarasa; Marcus Flather; Philippe Gabriel Steg

doi:10.1016/j.ahj.2004.03.038

Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI)

Carlo Di Mario, Leonardo Bolognese, Luc Maillard, Dariusz Dudek, Giampaolo Gambarati, Antonio Manari, Vincenzo Guiducci, Giampiero Patrizi, Luigi Cesare Rusconi, Giancarlo Piovaccari, Agnes Ricard Hibon, Vanessa Belpomme, Ciro Indolfi, Zoran Olivari, Giuseppe Steffenino, Krzysztof Zmudka, Flavio Airoldi, Rita Panzarasa, Marcus Flather, Philippe Gabriel Steg

Research output: Contribution to journal › Article › peer-review

39 Citations (Scopus)

Abstract

Most patients with acute myocardial infarction (AMI) are admitted to hospitals without percutaneous transluminal coronary angioplasty (PTCA) facilities or are initially managed in a prehospital mobile unit. Thrombolysis remains the most readily available reperfusion treatment in those settings, but the optimal subsequent strategy in those patients is unclear. If a mechanical recanalization is likely to be performed in an emergency, it is probably desirable that the patient receives abciximab, the glycoprotein IIb/IIIa antagonist with the strongest evidence of benefit for angioplasty in AMI.

Original language	English
Pages (from-to)	378-85
Number of pages	8
Journal	American Heart Journal
Volume	148
Issue number	3
DOIs	https://doi.org/10.1016/j.ahj.2004.03.038
Publication status	Published - Sept 2004

Keywords

Antibodies, Monoclonal
Cost-Benefit Analysis
Drug Therapy, Combination
Emergency Medical Services
Humans
Immunoglobulin Fab Fragments
Myocardial Infarction
Plasminogen Activators
Platelet Glycoprotein GPIIb-IIIa Complex
Prospective Studies
Recombinant Proteins
Recurrence
Stents
Thrombolytic Therapy
Tissue Plasminogen Activator
Treatment Outcome

Access to Document

10.1016/j.ahj.2004.03.038

Cite this

Di Mario, C., Bolognese, L., Maillard, L., Dudek, D., Gambarati, G., Manari, A., Guiducci, V., Patrizi, G., Rusconi, L. C., Piovaccari, G., Hibon, A. R., Belpomme, V., Indolfi, C., Olivari, Z., Steffenino, G., Zmudka, K., Airoldi, F., Panzarasa, R., Flather, M., & Steg, P. G. (2004). Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI). American Heart Journal, 148(3), 378-85. https://doi.org/10.1016/j.ahj.2004.03.038

@article{99bcd147bcfa4b64ba184b09ecb180c4,

title = "Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI)",

abstract = "Most patients with acute myocardial infarction (AMI) are admitted to hospitals without percutaneous transluminal coronary angioplasty (PTCA) facilities or are initially managed in a prehospital mobile unit. Thrombolysis remains the most readily available reperfusion treatment in those settings, but the optimal subsequent strategy in those patients is unclear. If a mechanical recanalization is likely to be performed in an emergency, it is probably desirable that the patient receives abciximab, the glycoprotein IIb/IIIa antagonist with the strongest evidence of benefit for angioplasty in AMI.",

keywords = "Antibodies, Monoclonal, Cost-Benefit Analysis, Drug Therapy, Combination, Emergency Medical Services, Humans, Immunoglobulin Fab Fragments, Myocardial Infarction, Plasminogen Activators, Platelet Glycoprotein GPIIb-IIIa Complex, Prospective Studies, Recombinant Proteins, Recurrence, Stents, Thrombolytic Therapy, Tissue Plasminogen Activator, Treatment Outcome",

author = "{Di Mario}, Carlo and Leonardo Bolognese and Luc Maillard and Dariusz Dudek and Giampaolo Gambarati and Antonio Manari and Vincenzo Guiducci and Giampiero Patrizi and Rusconi, {Luigi Cesare} and Giancarlo Piovaccari and Hibon, {Agnes Ricard} and Vanessa Belpomme and Ciro Indolfi and Zoran Olivari and Giuseppe Steffenino and Krzysztof Zmudka and Flavio Airoldi and Rita Panzarasa and Marcus Flather and Steg, {Philippe Gabriel}",

year = "2004",

month = sep,

doi = "10.1016/j.ahj.2004.03.038",

language = "English",

volume = "148",

pages = "378--85",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "Elsevier",

number = "3",

}

Di Mario, C, Bolognese, L, Maillard, L, Dudek, D, Gambarati, G, Manari, A, Guiducci, V, Patrizi, G, Rusconi, LC, Piovaccari, G, Hibon, AR, Belpomme, V, Indolfi, C, Olivari, Z, Steffenino, G, Zmudka, K, Airoldi, F, Panzarasa, R, Flather, M & Steg, PG 2004, 'Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI)', American Heart Journal, vol. 148, no. 3, pp. 378-85. https://doi.org/10.1016/j.ahj.2004.03.038

TY - JOUR

T1 - Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI)

AU - Di Mario, Carlo

AU - Bolognese, Leonardo

AU - Maillard, Luc

AU - Dudek, Dariusz

AU - Gambarati, Giampaolo

AU - Manari, Antonio

AU - Guiducci, Vincenzo

AU - Patrizi, Giampiero

AU - Rusconi, Luigi Cesare

AU - Piovaccari, Giancarlo

AU - Hibon, Agnes Ricard

AU - Belpomme, Vanessa

AU - Indolfi, Ciro

AU - Olivari, Zoran

AU - Steffenino, Giuseppe

AU - Zmudka, Krzysztof

AU - Airoldi, Flavio

AU - Panzarasa, Rita

AU - Flather, Marcus

AU - Steg, Philippe Gabriel

PY - 2004/9

Y1 - 2004/9

N2 - Most patients with acute myocardial infarction (AMI) are admitted to hospitals without percutaneous transluminal coronary angioplasty (PTCA) facilities or are initially managed in a prehospital mobile unit. Thrombolysis remains the most readily available reperfusion treatment in those settings, but the optimal subsequent strategy in those patients is unclear. If a mechanical recanalization is likely to be performed in an emergency, it is probably desirable that the patient receives abciximab, the glycoprotein IIb/IIIa antagonist with the strongest evidence of benefit for angioplasty in AMI.

AB - Most patients with acute myocardial infarction (AMI) are admitted to hospitals without percutaneous transluminal coronary angioplasty (PTCA) facilities or are initially managed in a prehospital mobile unit. Thrombolysis remains the most readily available reperfusion treatment in those settings, but the optimal subsequent strategy in those patients is unclear. If a mechanical recanalization is likely to be performed in an emergency, it is probably desirable that the patient receives abciximab, the glycoprotein IIb/IIIa antagonist with the strongest evidence of benefit for angioplasty in AMI.

KW - Antibodies, Monoclonal

KW - Cost-Benefit Analysis

KW - Drug Therapy, Combination

KW - Emergency Medical Services

KW - Humans

KW - Immunoglobulin Fab Fragments

KW - Myocardial Infarction

KW - Plasminogen Activators

KW - Platelet Glycoprotein GPIIb-IIIa Complex

KW - Prospective Studies

KW - Recombinant Proteins

KW - Recurrence

KW - Stents

KW - Thrombolytic Therapy

KW - Tissue Plasminogen Activator

KW - Treatment Outcome

U2 - 10.1016/j.ahj.2004.03.038

DO - 10.1016/j.ahj.2004.03.038

M3 - Article

C2 - 15389222

SN - 0002-8703

VL - 148

SP - 378

EP - 385

JO - American Heart Journal

JF - American Heart Journal

IS - 3

ER -